Nanomedicine News

RSS

TechConnect 2015: Lehigh to Present Nanoscale Device to Capture Tumor Cells

Lehigh University engineers, materials scientists and chemists will present their innovative breakthroughs to a national showcase of investors and industrial partners at the TechConnect 2015 World Innovation Conference and National Innovation Showcase in Washington on June 14-17.

12 Jun 2015

Trojan Horse Nanoparticles Release Payload to Turn Off XBP1 Gene to Treat Ovarian Tumors

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year.

12 Jun 2015

BIND and Macrophage Therapeutics Collaborate to Engineer Accurins with Manocept Targeting Platform

BIND Therapeutics, Inc., a clinical-stage nanomedicine company developing targeted and programmable therapeutics called Accurins™, and Macrophage Therapeutics, a subsidiary of Navidea Biopharmaceuticals, Inc. today announced they have entered into a research collaboration to engineer Accurins with the Manocept™ targeting platform that enables selective, efficient binding to CD206 positive disease-associated macrophages.

12 Jun 2015

Arcturus, Janssen Collaborate to Commercialize RNA-Based Drugs Using Nanoparticle Delivery Platform

Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the agreement, facilitated by J&J Innovation, the parties will work together to develop and commercialize RNA-based drug products for the treatment of specified diseases using Arcturus' UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery platform.

12 Jun 2015

Merrimack Expands Phase 1 Study of Iron Oxide Nanoparticle Marker for nal-IRI Tumor Response Prediction

Merrimack Pharmaceuticals, Inc. today announced the initiation of clinical imaging assessing the use of a potential marker for delivery of MM-398 (irinotecan liposome injection), also known as "nal-IRI," to metastatic breast cancer.

12 Jun 2015

Battery-Less Implantable CardioMEMS Sensor Device for Advanced Heart Failure Patients

Cardiologists at The Mount Sinai Hospital have begun implanting tiny, state-of-the-art microchip sensors in patients with advanced heart failure to better monitor symptoms and reduce their chances of returning to the hospital.

12 Jun 2015

Nanoparticles Specifically Target Tough Cancer Stem Cells

Many cancer patients survive treatment only to have a recurrence within a few years. Recurrences and tumor spreading are likely due to cancer stem cells that can be tough to kill with conventional cancer drugs.

11 Jun 2015

Immune Pharmaceuticals Successfully Incorporates Cyclosporine A into Biodegradable Nano-Capsules

Immune Pharmaceuticals Inc. announced today that it has entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclosporine A.

11 Jun 2015

Positive Intermediate Results from Nanobiotix’s NBTXR3 Phase I/II Clinical Trial in Head and Neck Cancer

NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial.

10 Jun 2015

Nanoparticles Arrest Destruction of Beta Cells and Avoid Diabetes Development

Two years ago, the Immunology of Diabetes Research Group at the Germans Trias Research Institute (at Universitat Autònoma de Barcelona - Campus of International Excellence Sphere) reported a new experimental immunotherapy that prevented the onset of Type 1 Diabetes in mice predisposed to the disease.

10 Jun 2015

Nanomedicine News

TechConnect 2015: Lehigh to Present Nanoscale Device to Capture Tumor Cells

Trojan Horse Nanoparticles Release Payload to Turn Off XBP1 Gene to Treat Ovarian Tumors

BIND and Macrophage Therapeutics Collaborate to Engineer Accurins with Manocept Targeting Platform

Arcturus, Janssen Collaborate to Commercialize RNA-Based Drugs Using Nanoparticle Delivery Platform

Merrimack Expands Phase 1 Study of Iron Oxide Nanoparticle Marker for nal-IRI Tumor Response Prediction

Battery-Less Implantable CardioMEMS Sensor Device for Advanced Heart Failure Patients

Nanoparticles Specifically Target Tough Cancer Stem Cells

Immune Pharmaceuticals Successfully Incorporates Cyclosporine A into Biodegradable Nano-Capsules

Positive Intermediate Results from Nanobiotix’s NBTXR3 Phase I/II Clinical Trial in Head and Neck Cancer

Nanoparticles Arrest Destruction of Beta Cells and Avoid Diabetes Development

Laser-Induced Graphene for Printable and Biomedical Applications

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Novel Technique Dramatically Increases Graphene's Elasticity

Cigarette Waste as a Source for Sustainable Supercapacitors

Co-Solvent-Driven Laser Assembly of Gold Nanorods

Breaking Barriers in Thin-Film Deposition with ATLANT 3D’s DALP Technology

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

Sponsored Content

Unlocking Material Behavior at the Microscale Using Nanoindentation

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination